Intervention Review

You have free access to this content

Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage

  1. Merih I Baharoglu1,
  2. Menno R Germans2,
  3. Gabriel JE Rinkel3,
  4. Ale Algra4,
  5. Marinus Vermeulen1,
  6. Jan van Gijn5,
  7. Yvo BWEM Roos1,*

Editorial Group: Cochrane Stroke Group

Published Online: 30 AUG 2013

Assessed as up-to-date: 4 FEB 2013

DOI: 10.1002/14651858.CD001245.pub2


How to Cite

Baharoglu MI, Germans MR, Rinkel GJE, Algra A, Vermeulen M, van Gijn J, Roos YBWEM. Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage. Cochrane Database of Systematic Reviews 2013, Issue 8. Art. No.: CD001245. DOI: 10.1002/14651858.CD001245.pub2.

Author Information

  1. 1

    University of Amsterdam, Department of Neurology, Academic Medical Centre, Amsterdam, Netherlands

  2. 2

    University of Amsterdam, Department of Neurosurgery, Academic Medical Centre, Amsterdam, Netherlands

  3. 3

    University Medical Center Utrecht, Department of Neurology and Neurosurgery, Utrecht, Netherlands

  4. 4

    University Medical Center Utrecht, Julius Center for Health Sciences and Primary Care/University Department of Neurology and Neurosurgery, Utrecht, Netherlands

  5. 5

    University Medical Center Utrecht, Department of Neurology, Utrecht, Netherlands

*Yvo BWEM Roos, Department of Neurology, Academic Medical Centre, University of Amsterdam, PO Box 22660, Amsterdam, 1100 DD, Netherlands. y.b.roos@amc.uva.nl.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 30 AUG 2013

SEARCH

[Figure 1]
Figure 1. Study flow diagram.
[Figure 2]
Figure 2. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
[Figure 3]
Figure 3. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
[Analysis 1.1]
Analysis 1.1. Comparison 1 Antifibrinolytic treatment versus control treatment with or without placebo, Outcome 1 Poor outcome (death, vegetative or severe disability on Glasgow Outcome Scale at end of follow-up): open versus blind studies.
[Analysis 1.2]
Analysis 1.2. Comparison 1 Antifibrinolytic treatment versus control treatment with or without placebo, Outcome 2 Death from all causes at end of follow up: open versus blind studies.
[Analysis 1.3]
Analysis 1.3. Comparison 1 Antifibrinolytic treatment versus control treatment with or without placebo, Outcome 3 Rebleeding reported at end of follow up: open versus blind studies.
[Analysis 1.4]
Analysis 1.4. Comparison 1 Antifibrinolytic treatment versus control treatment with or without placebo, Outcome 4 Confirmed rebleeding at end of follow-up (sensitivity analysis): open versus blind studies.
[Analysis 1.5]
Analysis 1.5. Comparison 1 Antifibrinolytic treatment versus control treatment with or without placebo, Outcome 5 Rebleeding reported at end of follow-up: trials with and without ischaemia prevention according to treatment duration.
[Analysis 1.6]
Analysis 1.6. Comparison 1 Antifibrinolytic treatment versus control treatment with or without placebo, Outcome 6 Cerebral ischaemia reported at end of follow-up: open versus blind studies.
[Analysis 1.7]
Analysis 1.7. Comparison 1 Antifibrinolytic treatment versus control treatment with or without placebo, Outcome 7 Confirmed cerebral ischaemia at end of follow-up (sensitivity analysis): open versus blind studies.
[Analysis 1.8]
Analysis 1.8. Comparison 1 Antifibrinolytic treatment versus control treatment with or without placebo, Outcome 8 Hydrocephalus reported at end of follow-up: open versus blind studies.
[Analysis 1.9]
Analysis 1.9. Comparison 1 Antifibrinolytic treatment versus control treatment with or without placebo, Outcome 9 Confirmed hydrocephalus at end of follow up (sensitivity analysis): open versus blind studies.
[Analysis 1.10]
Analysis 1.10. Comparison 1 Antifibrinolytic treatment versus control treatment with or without placebo, Outcome 10 Hydrocephalus reported at end of follow-up: trials with and without ischaemia prevention according to treatment duration.
[Analysis 1.11]
Analysis 1.11. Comparison 1 Antifibrinolytic treatment versus control treatment with or without placebo, Outcome 11 Poor outcome (death, vegetative or severe disability on Glasgow Outcome Scale at end of follow-up): trials with and without ischaemia prevention according to treatment duration.
[Analysis 1.12]
Analysis 1.12. Comparison 1 Antifibrinolytic treatment versus control treatment with or without placebo, Outcome 12 Death from all causes at end of follow-up: trials with and without ischaemia prevention according to treatment duration.
[Analysis 1.13]
Analysis 1.13. Comparison 1 Antifibrinolytic treatment versus control treatment with or without placebo, Outcome 13 Cerebral ischaemia reported at end of follow-up: trials with and without ischaemia prevention according to treatment duration.